Pharma Sector

DSP Healthcare Fund generated the highest returns of 69.80% in the last one yearNifty pharma index grew by 51.5% in last one year

Sales in February rebounded, registering 12.1% growth year-on-year

Earlier this month, the US FDA downplayed the risk associated with ranitidineThe safety alert triggered considerable chaos in the pharmaceutical sector worldwide

Mylan global president Rajiv Malik said the firm had been investing close to about $400 mn or $450 mn towards capex every year and half of it in IndiaCurrently Maylan has 21 facilities and 15,000 employees working in India

India imports almost 80% of its API requirement from ChinaOnce the list of such APIs are prepared, it will be submitted to the Department of Pharmacueticals

Natco Pharma is focusing on filing of the cancer treatment drugs in China as part of its strategy to diversify business in emerging markets amid headwinds in the USChina's pharma market is likely to grow at 3-6% to $140-170 bn by 2023 as against Brazil which is likely to grow at 5-8% to $30-43 bn

Torrent Pharma derives 45% of its revenue from India, making the domestic market crucial for its earningsRevenues in India grew 9%, and if one adjusts for the impact of discontinued products, revenue growth will be 11% on a like-to-like basis

Volumes dropped for the second consecutive month in JuneThe slowdown intensified from May, when growth dropped to 7%

The story of how India’s largest generics drug maker dealt with the discovery of deep gaps in its drug trial data

The closing of the transaction is subject to various customary closing conditionsShares of Dr Reddy's Lab traded at ₹2529.65 on BSE, down 2.18% in the morning